BOTHELL, Wash.--(BUSINESS WIRE)--BTG plc (LSE: BTG), the global specialist healthcare company, today highlights the commencement of the KNOCOUT PE study. The KNOCOUT PE study will measure how ...
BOTHELL, Wash.--(BUSINESS WIRE)--BTG plc (LSE: BTG), the global healthcare company, today highlighted OPTALYSE PE one year trial results, presented at the International Society on Endovascular Therapy ...
BOTHELL, Wash.-- EKOS Corporation announced today the EKOS EkoSonic® Endovascular System is the first endovascular device approved for the treatment of pulmonary embolism (PE). The EkoSonic® System, ...
BTG Receives U.S. FDA 510(k) Clearance for EKOS® Control Unit 4.0 London, UK, 27 February 2017: BTG plc (LSE: BTG), the global specialist healthcare company, today announced U.S. Food and Drug ...
Bothell, WA, 22 May 2017: BTG plc (LSE: BTG), the global specialist healthcare company, today highlights the results of the OPTALYSE PE trial, presented at the American Thoracic Society International ...
Please provide your email address to receive an email when new articles are posted on . Patients with chronic deep vein thrombosis and postthrombotic syndrome can be treated safely and effectively ...
BTG plc, the global healthcare company, highlighted the presentation of OPTALYSE PE trial results at the Society for Cardiovascular Angiography and Interventions in San Diego, California. The findings ...
Mediclinic Parkview Hospital’s cutting-edge interventional cardiology procedure saves patient’s life
EKOS therapy, a minimally invasive system for dissolving thrombus, was a success Dr Ahmad Mustafa, Consultant Interventional Cardiologist at Mediclinic Parkview Hospital with his patient (centre), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback